290 related articles for article (PubMed ID: 15653676)
1. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells.
Marcus AI; Peters U; Thomas SL; Garrett S; Zelnak A; Kapoor TM; Giannakakou P
J Biol Chem; 2005 Mar; 280(12):11569-77. PubMed ID: 15653676
[TBL] [Abstract][Full Text] [Related]
2. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells.
Nakai R; Iida S; Takahashi T; Tsujita T; Okamoto S; Takada C; Akasaka K; Ichikawa S; Ishida H; Kusaka H; Akinaga S; Murakata C; Honda S; Nitta M; Saya H; Yamashita Y
Cancer Res; 2009 May; 69(9):3901-9. PubMed ID: 19351824
[TBL] [Abstract][Full Text] [Related]
3. Interaction of the mitotic kinesin Eg5 inhibitor monastrol with P-glycoprotein.
Peters T; Lindenmaier H; Haefeli WE; Weiss J
Naunyn Schmiedebergs Arch Pharmacol; 2006 Jan; 372(4):291-9. PubMed ID: 16365780
[TBL] [Abstract][Full Text] [Related]
4. Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint.
Chin GM; Herbst R
Mol Cancer Ther; 2006 Oct; 5(10):2580-91. PubMed ID: 17041103
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of new tetrahydro-beta-carbolines as inhibitors of the mitotic kinesin Eg5.
Sunder-Plassmann N; Sarli V; Gartner M; Utz M; Seiler J; Huemmer S; Mayer TU; Surrey T; Giannis A
Bioorg Med Chem; 2005 Nov; 13(22):6094-111. PubMed ID: 16084101
[TBL] [Abstract][Full Text] [Related]
6. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5.
Kapoor TM; Mayer TU; Coughlin ML; Mitchison TJ
J Cell Biol; 2000 Sep; 150(5):975-88. PubMed ID: 10973989
[TBL] [Abstract][Full Text] [Related]
7. In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities.
DeBonis S; Skoufias DA; Lebeau L; Lopez R; Robin G; Margolis RL; Wade RH; Kozielski F
Mol Cancer Ther; 2004 Sep; 3(9):1079-90. PubMed ID: 15367702
[TBL] [Abstract][Full Text] [Related]
8. Eg5 inhibitor YL001 induces mitotic arrest and inhibits tumor proliferation.
Wang Y; Wu X; Du M; Chen X; Ning X; Chen H; Wang S; Liu J; Liu Z; Li R; Fu G; Wang C; McNutt MA; Zhou D; Yin Y
Oncotarget; 2017 Jun; 8(26):42510-42524. PubMed ID: 28489567
[TBL] [Abstract][Full Text] [Related]
9. Discovery of tetrahydro-beta-carbolines as inhibitors of the mitotic kinesin KSP.
Liu F; Yu LQ; Jiang C; Yang L; Wu WT; You QD
Bioorg Med Chem; 2010 Jun; 18(12):4167-77. PubMed ID: 20537544
[TBL] [Abstract][Full Text] [Related]
10. Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance.
Garcia-Saez I; Skoufias DA
Biochem Pharmacol; 2021 Feb; 184():114364. PubMed ID: 33310050
[TBL] [Abstract][Full Text] [Related]
11. Proteome analysis of apoptosis signaling by S-trityl-L-cysteine, a potent reversible inhibitor of human mitotic kinesin Eg5.
Kozielski F; Skoufias DA; Indorato RL; Saoudi Y; Jungblut PR; Hustoft HK; Strozynski M; Thiede B
Proteomics; 2008 Jan; 8(2):289-300. PubMed ID: 18186019
[TBL] [Abstract][Full Text] [Related]
12. Growth arrest and apoptosis induced by kinesin Eg5 inhibitor K858 and by its 1,3,4-thiadiazoline analogue in tumor cells.
Giantulli S; De Iuliis F; Taglieri L; Carradori S; Menichelli G; Morrone S; Scarpa S; Silvestri I
Anticancer Drugs; 2018 Aug; 29(7):674-681. PubMed ID: 29738338
[TBL] [Abstract][Full Text] [Related]
13. Significant decrease of ADP release rate underlies the potent activity of dimethylenastron to inhibit mitotic kinesin Eg5 and cancer cell proliferation.
Sun L; Sun X; Xie S; Yu H; Zhong D
Biochem Biophys Res Commun; 2014 May; 447(3):465-70. PubMed ID: 24732354
[TBL] [Abstract][Full Text] [Related]
14. A novel action of terpendole E on the motor activity of mitotic Kinesin Eg5.
Nakazawa J; Yajima J; Usui T; Ueki M; Takatsuki A; Imoto M; Toyoshima YY; Osada H
Chem Biol; 2003 Feb; 10(2):131-7. PubMed ID: 12618185
[TBL] [Abstract][Full Text] [Related]
15. A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor.
Xing ND; Ding ST; Saito R; Nishizawa K; Kobayashi T; Inoue T; Oishi S; Fujii N; Lv JJ; Ogawa O; Nishiyama H
Asian J Androl; 2011 Mar; 13(2):236-41. PubMed ID: 21297652
[TBL] [Abstract][Full Text] [Related]
16. Monastrol, a prototype anti-cancer drug that inhibits a mitotic kinesin, induces rapid bursts of axonal outgrowth from cultured postmitotic neurons.
Haque SA; Hasaka TP; Brooks AD; Lobanov PV; Baas PW
Cell Motil Cytoskeleton; 2004 May; 58(1):10-6. PubMed ID: 14983520
[TBL] [Abstract][Full Text] [Related]
17. A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models.
Ye XS; Fan L; Van Horn RD; Nakai R; Ohta Y; Akinaga S; Murakata C; Yamashita Y; Yin T; Credille KM; Donoho GP; Merzoug FF; Li H; Aggarwal A; Blanchard K; Westin EH
Mol Cancer Ther; 2015 Nov; 14(11):2463-72. PubMed ID: 26304237
[TBL] [Abstract][Full Text] [Related]
18. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5.
Shi J; Orth JD; Mitchison T
Cancer Res; 2008 May; 68(9):3269-76. PubMed ID: 18451153
[TBL] [Abstract][Full Text] [Related]
19. HSP70 regulates Eg5 distribution within the mitotic spindle and modulates the cytotoxicity of Eg5 inhibitors.
Fang CT; Kuo HH; Hsu SC; Yih LH
Cell Death Dis; 2020 Sep; 11(8):715. PubMed ID: 32873777
[TBL] [Abstract][Full Text] [Related]
20. Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents.
Brier S; Lemaire D; DeBonis S; Forest E; Kozielski F
J Mol Biol; 2006 Jul; 360(2):360-76. PubMed ID: 16780877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
